The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models

BACKGROUND: Cetuximab is the only targeted agent approved for the treatment of head and neck squamous cell carcinomas (HNSCC), but low response rates and disease progression are frequently reported. As the phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) pathways have an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: D'Amato, V, Rosa, R, D'Amato, C, Formisano, L, Marciano, R, Nappi, L, Raimondo, L, Di Mauro, C, Servetto, A, Fusciello, C, Veneziani, B M, De Placido, S, Bianco, R
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2014
Schlagworte:
Translational Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4056056/
https://ncbi.nlm.nih.gov/pubmed/24823695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.241
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge